Minimal Residual Disease Testing Market worth $2.3 billion by 2027
The report "Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027" is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0%. Increasing prevalence of cancer and hematological malignancies, rising initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the minimal residual disease testing market.
Browse 121 market data Tables and 40 Figures spread through 179 Pages and in-depth TOC on "Minimal Residual Disease Testing Market - Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/minimal-residual-disease-testing-market-215386038.html
The PCR segment accounted for the largest share of the minimal residual disease testing market, by technology segment, in 2021
Based on technology, the minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). The polymerase chain reaction technology segment accounted for the largest share in 2021. The large share of this segment is due to the device being easy to use, being easily available with relative sensitivity and cost efficiency.
Hematological Malignancies segment to register the highest growth rate during the forecast period
Based on applications, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies segment accounted for the largest share primarily due to factors such as the increasing incidence of leukemia and lymphoma and the need to continuously monitor the patients with these diseases.
The hospitals & specialty clinics accounted for the largest share of the minimal residual disease testing market, by end user segment, in 2021
Based on end users, the minimal residual disease testing market has been segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2021, the hospitals & specialty clinics segment accounted for the largest share of this market, due to availability of advanced diagnostic devices with skilled and professional healthcare workforce.
North America is the largest regional market for minimal residual disease testing market
The global minimal residual disease testing market has been segmented into four major regions—North America, Europe, the Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the minimal residual disease testing market. The large share of this regional segment can be attributed to the growing incidence of hematological malignancies which include leukemia and lymphoma, well-developed healthcare systems in the US and Canada, the presence of many leading clinical laboratories across nation, and the easy availability of advanced diagnostic instruments.
The major players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China), among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Minimal Residual Disease Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
